Salary in the range of £28,500 - £38,000 dependent upon qualifications and experience.
Job Ref: MI/14/21-3
Duration of post: 3 Years
The Cancer Research UK Manchester Institute is a centre for excellence in cancer research (
www.cruk.manchester.ac.uk). We occupy state-of-the-art laboratories and provide exceptional core facilities, including next generation sequencing, mass-spectrometry, advanced imaging, bioinformatics, histology, and flow cytometry. We are core-funded by Cancer Research UK (
www.cancerresearchuk.org), the world’s largest cancer organisation, are an Institute of The University of Manchester (
www.manchester.ac.uk), and are adjacent to The Christie NHS Foundation Trust (
www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes in a vibrant and dynamic city surrounded by beautiful countryside and with excellent national and international transport links.
An exciting opportunity has arisen for a motivated post-doctoral scientist within Prof. Caroline Dive’s Clinical and Experimental Pharmacology Group to conduct cutting edge translational research on Small Cell Lung Cancer. The successful candidate will focus on unique lung cancer circulating tumour cell (CTC) derived explant tumour models (CDX) and analysis of CTCs isolated from lung cancer patients (see Hodgkinson et al., Nature Medicine, 2014). He/she will evaluate a developing set of whole exome and RNA sequencing data from SCLC CDX models which mimic patient responses to standard chemotherapy in order to explore and validate underpinning drug resistance mechanisms. They will also exploit these new models to discover new drug targets and they will assess and interrogate the impact of novel targeted therapy combinations in these CDX models generated from chemo-sensitive and chemo-refractory patients. This post, core funded by the CRUK Manchester Institute, sits within the CRUK Lung Cancer Centre of Excellence, a partnership between Manchester and University College London with associated opportunities for collaboration.
You will have a PhD in oncology, cell biology or molecular pharmacology and have a strong desire to see your research translated for patient benefit.
For any informal enquiries about this post, please contact Prof Caroline Dive, email:
[email protected] or her Preclinical Pharmacology Team lead Dr Christopher Morrow, email:
[email protected].
To apply for this position, please visit our website:
www.cruk.manchester.ac.uk For applicants who are unable to download the information from our website, please contact the HR Department on 0161 446 3231, email:
[email protected] to have the information sent by post.
The deadline for receipt of applications is: 27 April 2015.
